Human cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents

被引:29
作者
Kubara, Philip M. [1 ]
Kerneis-Golsteyn, Sophie [1 ]
Studeny, Aurelie [2 ]
Lanser, Brittany B. [1 ]
Meijer, Laurent [3 ]
Golsteyn, Roy M. [1 ]
机构
[1] Univ Lethbridge, Dept Biol Sci, Canc Cell Lab, Lethbridge, AB T1K 3M4, Canada
[2] Inst Rech Servier, F-78290 Croissy Sur Seine, France
[3] CNRS, Biol Stn, F-29682 Roscoff, France
关键词
camptothecin; checkpoint adaptation; checkpoint kinase 1 (Chk1); cyclin-dependent kinase 1 (Cdk1); mitosis; mitotic catastrophe; CYCLIN-DEPENDENT KINASES; POLO-LIKE KINASE; CHECKPOINT KINASE-1; CANCER DEVELOPMENT; TOPOISOMERASE-II; MAMMALIAN-CELLS; S-PHASE; PHOSPHORYLATION; CHK1; APOPTOSIS;
D O I
10.1042/BJ20120385
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the present paper, we report that mitosis is a key step in the cellular response to genotoxic agents in human cells. Cells with damaged DNA recruit gamma H2AX (phosphorylated histone H2AX), phosphorylate Chk1 (checkpoint kinase 1) and arrest in the G(2)-phase of the cell cycle. Strikingly, nearly all cells escape the DNA damage checkpoint and become rounded, by a mechanism that correlates with Chk1 dephosphorylation. The rounded cells are alive and in mitosis as measured by low phospho-Tyr(15) Cdk1 (cyclin-dependent kinase 1), high Cdk activity, active Plk1 (Polo-like kinase 1) and high phospho-histone H3 signals. This phenomenon is independent of the type of DNA damage, but is dependent on pharmacologically relevant doses of genotoxicity. Entry into mitosis is likely to be caused by checkpoint adaptation, and the HT-29 cell-based model provides a powerful experimental system in which to explore its molecular basis. We propose that mitosis with damaged DNA is a biologically significant event because it may cause genomic rearrangement in cells that survive genotoxic damage.
引用
收藏
页码:373 / 381
页数:9
相关论文
共 50 条
[1]   DNA damage checkpoints: from initiation to recovery or adaptation [J].
Bartek, Jiri ;
Lukas, Jiri .
CURRENT OPINION IN CELL BIOLOGY, 2007, 19 (02) :238-245
[2]   CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases [J].
Bettayeb, K. ;
Oumata, N. ;
Echalier, A. ;
Ferandin, Y. ;
Endicott, J. A. ;
Galons, H. ;
Meijer, L. .
ONCOGENE, 2008, 27 (44) :5797-5807
[3]   OPINION γH2AX and cancer [J].
Bonner, William M. ;
Redon, Christophe E. ;
Dickey, Jennifer S. ;
Nakamura, Asako J. ;
Sedelnikova, Olga A. ;
Solier, Stephanie ;
Pommier, Yves .
NATURE REVIEWS CANCER, 2008, 8 (12) :957-967
[4]   Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment [J].
Borgne, A. ;
Versteege, I. ;
Mahe, M. ;
Studeny, A. ;
Leonce, S. ;
Naime, I. ;
Rodriguez, M. ;
Hickman, J. A. ;
Meijer, L. ;
Golsteyn, R. M. .
ONCOGENE, 2006, 25 (56) :7361-7372
[5]   Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage [J].
Busino, L ;
Donzelli, M ;
Chiesa, M ;
Guardavaccaro, D ;
Ganoth, D ;
Dorrello, NV ;
Hershko, A ;
Pagano, M ;
Draetta, GF .
NATURE, 2003, 426 (6962) :87-91
[6]   An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells [J].
Cahuzac, Nathalie ;
Studeny, Aurelie ;
Marshall, Kris ;
Versteege, Isabella ;
Wetenhall, Kate ;
Pfeiffer, Bruno ;
Leonce, Stephane ;
Hickman, John A. ;
Pierre, Alain ;
Golsteyn, Roy M. .
CANCER LETTERS, 2010, 289 (02) :178-187
[7]   Targeting the S and G2 checkpoint to treat cancer [J].
Chen, Tao ;
Stephens, Peter A. ;
Middleton, Fiona K. ;
Curtin, Nicola J. .
DRUG DISCOVERY TODAY, 2012, 17 (5-6) :194-202
[8]   DNA damage checkpoint inactivation: Adaptation and recovery [J].
Clemenson, Celine ;
Marsolier-Kergoat, Marie-Claude .
DNA REPAIR, 2009, 8 (09) :1101-1109
[9]  
Clifford B, 2003, CANCER RES, V63, P4074
[10]   New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network [J].
Dai, Yun ;
Grant, Steven .
CLINICAL CANCER RESEARCH, 2010, 16 (02) :376-383